Incyte Corporation INCY announced results from a 28-day,
placebo-controlled, dose-escalation Phase II proof-of-concept clinical
trial involving 50 patients with chronic plaque psoriasis for its
proprietary oral JAK1 inhibitor, INCB39110. The results were presented
by Robert Bissonnette, M.D., President of Innovaderm Research Inc. and
co-lead investigator, today at the European Academy of Dermatology and
Venereology (EADV) Congress in Istanbul, Turkey.
In the trial, evidence of efficacy was observed in patients treated with
INCB39110 at all doses as measured by static physician global assessment
(sPGA) and psoriasis area and severity index (PASI) as compared to
patients treated with placebo. INCB39110 was generally well-tolerated
with no evidence of myelosuppression.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in